SLU-PP-332: Insights Into an ERR Agonist Enhancing Exercise Endurance

Research brief

SLU-PP-332 shows promise as an ERR agonist mimicking exercise effects, enhancing oxidative metabolism, and improving endurance [PMID: 41850449; PMID: 41688415]. In vitro metabolism studies help address its potential misuse in sports [PMID: 41588687].

Key findings

• SLU-PP-332 acts as an ERR agonist, enhancing oxidative muscle metabolism [PMID: 41850449]. • It increases exercise endurance and has potential in treating metabolic disorders [PMID: 41688415]. • Chemical modification of SLU-PP-332 improves drug-like properties without losing efficacy [PMID: 41850449]. • SLU-PP-332 metabolism studies are crucial for doping control efforts [PMID: 41588687].

Detailed research context

Introduction

Estrogen-related receptors (ERRs) are crucial nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. These properties make ERRs promising targets for exercise mimetic therapeutics, particularly for individuals unable to engage in regular physical activity. Among the emerging compounds in this domain is SLU-PP-332, a synthetic ERR agonist that mimics the physiological effects of exercise [PMID: 41421047; PMID: 41850449].

SLU-PP-332 and Its Mechanism

SLU-PP-332 is designed to engage with ERRs to enhance oxidative muscle fiber formation and fatty acid oxidation, leading to improved exercise endurance [PMID: 41850449]. It uses a structure that supports ERRa, ERRß, and ERRγ agonism, enabling it to improve aerobic performance and possibly protect against cardiac dysfunction [PMID: 41688415]. Although not orally bioavailable like SLU-PP-915, SLU-PP-332 remains a potent tool in exercise and metabolic research [PMID: 41421047].

Applications in Disease Models

In murine models of metabolic syndrome, SLU-PP-332 not only increased exercise capability but also showed potential in boosting energy expenditure and insulin sensitivity. Such effects position SLU-PP-332 as an attractive agent for managing conditions like obesity and Type 2 diabetes by activating metabolic pathways similar to those triggered by physical activity [PMID: 41688415].

Chemical Optimization Efforts

Research aimed at chemically optimizing SLU-PP-332 has focused on enhancing its drug-like properties without compromising its efficacy. By modifying pharmacophoric elements, scientists have developed analogues with improved solubility, stability, and ligand efficiency [PMID: 41850449]. These insights are critical to developing next-generation exercise mimetics tailored for therapeutic use.

Metabolic Pathways and Doping Concerns

The potential misuse of SLU-PP-332 as a performance-enhancing drug is a notable concern for regulatory bodies like the World Anti-Doping Agency (WADA), which prohibits exercise mimetics. The in vitro metabolism of SLU-PP-332 has been thoroughly investigated, revealing a series of metabolites useful for doping control. The identification of these metabolites is crucial to ensure fair play in sports [PMID: 41588687; PMID: 41688415].

Conclusion

SLU-PP-332 represents a pioneering class of compounds in the realm of exercise mimetics, with wide-ranging applications in metabolic health and athletic performance. While promising, further studies are essential to fully explore its therapeutic potential, ensure its safety, and develop robust anti-doping detection methods. As research progresses, the role of SLU-PP-332 could extend beyond exercise mimetics to address broader health challenges associated with metabolic and cardiovascular disorders.

Source method

This research briefing is based on the verified PubMed records linked in the References & Citations section below.